Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval...
HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completin...
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the ri...
Lonza will build a new large-scale, commercial PSD-4 spray-drying facility in Bend, Oregon (US) to support a rapidly expanding market segment ...
Leading nutraceutical contract manufacturer secures prime Irvine facility near John Wayne Airport, marking its tenth operational site and further elevati...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, announced that it has dosed the first patien...
-Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...
Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider Nano-X Imaging Ltd. (“Nanox&rdqu...
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disea...
Eisai Co., Ltd. and Biogen Inc., announced that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of...
Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) ...
© 2026 Biopharma Boardroom. All Rights Reserved.
